A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Study summary

This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZD6244 in combination with selected chemotherapies will be evaluated. The study will also investigate how AZD6244 in combination with standard chemotherapies are absorbed, distributed and excreted by the body as well as the length of time that the drugs remain in the body. Initial and periodic assessments will establish patient response to the combination therapies

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedAZD6244 and Dacarbazine

Plus 3 other study approaches.

Who it may be forBreast Cancer · Breast Neoplasms

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 27, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?4 U.S. locations

Locations may change over time.

Who runs it?AstraZeneca

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1
Sponsor: AstraZeneca
Interventions being studied: Drug: AZD6244; Drug: Dacarbazine; Drug: Erlotinib; Drug: Docetaxel; Drug: Temsirolimus

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Chemotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Patients will have measurable and/or non-measurable disease, lacking curative options for whom the selected chemotherapy agents represent the standard of care
WHO performance status 0-1
Patients must be able to swallow AZD6244 capsules

Reasons someone may not be able to joinExclusion criteria

Prior treatment with a MEK inhibitor
Participation in a clinical study during the last 30 days or have not recovered from side effects of an investigational study drug
Brain metastases or spinal cord compression unless treated and stable (for at least 1 month) off steroids

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Research SiteDetroit, Michigan
Research SitePhiladelphia, Pennsylvania
Research SiteNashville, Tennessee
Research SiteHouston, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 27, 2026. Always confirm current availability with the study team.

View original record ↗